ADARx Pharmaceuticals

aid: adarx-pharmaceuticals
name: ADARx Pharmaceuticals
description: ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered at 5871 Oberlin Drive, San
  Diego, California, founded in 2019 and developing next-generation RNA therapeutics intended to control the expression of
  specific disease drivers with highly selective RNA-targeted medicines. Its proprietary platform spans RNA interference,
  RNA editing and targeted oligonucleotide delivery, engineered around compact, modular constructs the company says extend
  reach beyond the liver. The clinical pipeline is led by ADX-324 (onvuzosiran), an siRNA against prekallikrein now in the
  Phase 3 STOP-HAE study in hereditary angioedema, and ADX-038 (agazisiran), an siRNA against complement factor B in Phase
  2 for IgA nephropathy and C3 glomerulopathy, geographic atrophy and paroxysmal nocturnal hemoglobinuria; earlier programmes
  include ADX-626 (factor XI, thrombosis), ADX-077 (obesity) and ADX-199 (amyloid-beta precursor protein, neurodegeneration),
  plus undisclosed extrahepatic CNS, immunology and oncology work. The company closed an oversubscribed 200 million dollar
  Series C in August 2023 co-led by Bain Capital Life Sciences and TCGX, and entered a collaboration and license option agreement
  with AbbVie in May 2025. ADARx runs no developer program and publishes no product API, no developer portal and no API documentation;
  the only machine-readable surfaces reachable without credentials are the WordPress REST content APIs behind www.adarx.com
  and stophae.com, both catalogued here.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: true
  label: Hosted service · you call their endpoint
  confidence: high
  source:
  - openapi
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - authentication
  - security
  generated: '2026-09-03'
  method: derived
image: https://www.adarx.com/wp-content/uploads/2024/11/adarx-logo.png
url: https://raw.githubusercontent.com/api-evangelist/adarx-pharmaceuticals/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.23'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Biotechnology
- Biopharmaceutical
- RNA Therapeutics
- siRNA
- RNA Editing
- Clinical Trials
- Rare Disease
- Drug Development
- Life Sciences
- San Diego
- content-api
tags_raw:
- Company
- biotechnology
- biopharmaceuticals
- rna-therapeutics
- sirna
- rna-editing
- clinical-trials
- rare-disease
- drug-development
- life-sciences
- san-diego
- content-api
apis:
- aid: adarx-pharmaceuticals:adarx-com-website-wordpress-rest
  name: ADARx Pharmaceuticals Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the ADARx Pharmaceuticals website at www.adarx.com: the route index
    of the site''s content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://www.adarx.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://www.adarx.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: CapabilityMap
  url: capabilities/adarx-pharmaceuticals-capability-edges.yml
  name: ADARx Pharmaceuticals Business Capability Map
- type: Overlay
  url: overlays/adarx-pharmaceuticals-content-overlay.yaml
- type: Website
  url: https://www.adarx.com/
- type: About
  url: https://www.adarx.com/company/company-overview/
- type: Company
  url: https://www.adarx.com/company/
- type: Team
  url: https://www.adarx.com/company/team/
- type: Investors
  url: https://www.adarx.com/company/investors/
- type: Science
  url: https://www.adarx.com/science/science-overview/
- type: Technology
  url: https://www.adarx.com/science/technology/
- type: Pipeline
  url: https://www.adarx.com/pipeline/
- type: Publications
  url: https://www.adarx.com/science/publications/
- type: Patients
  url: https://www.adarx.com/patients/
- type: ClinicalTrials
  url: https://stophae.com/
- type: News
  url: https://www.adarx.com/news/
- type: BlogRSS
  url: https://www.adarx.com/feed/
- type: Careers
  url: https://www.adarx.com/careers/
- type: Contact
  url: https://www.adarx.com/contact/
- type: Support
  url: https://www.adarx.com/contact/
- type: TermsOfService
  url: https://www.adarx.com/terms-of-use/
- type: PrivacyPolicy
  url: https://www.adarx.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/adarx-pharmaceuticals-inc/
- type: Sitemap
  url: https://www.adarx.com/sitemap_index.xml
- type: SecondaryMarket
  url: https://www.nasdaqprivatemarket.com/
- type: Authentication
  url: authentication/adarx-pharmaceuticals-authentication.yml
- type: Conventions
  url: conventions/adarx-pharmaceuticals-conventions.yml
- type: Conformance
  url: conformance/adarx-pharmaceuticals-conformance.yml
- type: ErrorCatalog
  url: errors/adarx-pharmaceuticals-problem-types.yml
- type: Lifecycle
  url: lifecycle/adarx-pharmaceuticals-lifecycle.yml
- type: DataModel
  url: data-model/adarx-pharmaceuticals-data-model.yml
- type: JSONLD
  url: json-ld/adarx-pharmaceuticals-json-ld.yml
- type: WellKnown
  url: well-known/adarx-pharmaceuticals-well-known.yml
- type: DomainSecurity
  url: security/adarx-pharmaceuticals-domain-security.yml
- type: LLMsTxt
  url: llms/adarx-pharmaceuticals-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-06'
  status: enriched
  artifacts_added: 20
  pass: local-v1